Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs

21 de junho de 2020

Autores: Rosanna Marsella , Kim Ahrens, Rachel Wilkes, Andrew Trujillo and Mackenzie Dorr

Background – No study has directly compared the various treatment options for canine atopic dermatitis and
their effects on skin barrier.

Results – For CADESI, restricted maximum-likelihood ANOVA showed effect of time (P = 0034) and group x
time interaction (P = 0.0169). In the first two weeks, prednisone and oclacitinib were significantly lower than
controls (P = 0.019 and P = 0.015, respectively). Lokivetmab prevented flares. Due to variability, no significance
differences in pruritus were observed among groups. The TEWL increased with time in controls (P = 0.0237)
and ciclosporin (P = 0.04, axilla, D28 versus D0) but not in the oclacitinib and lokivetmab groups. CADESI-03 correlated with TEWL (P = 0.0043) and pruritus (P = 0.0283). Hydration did not correlate with any parameters.
Hydration decreased in controls and prednisone group (axilla, D14 versus D0, P = 0.004 and P = 0.027, respectively). AUC for hydration, over time, was higher for lokivetmab and oclacitinib than controls (P = 0.014 and
P = 0.04, respectively).
Conclusions and clinical importance – Lokivetmab prevented flares when given before challenge. Oclacitinib
and lokivetmab have some positive effects on skin barrier parameters.

Key words: lokivetmab, oclacitinib, prednisolone, atopic dermatitis

Palavras-chave: lokivetmab, ocalcitinib. prednisolona, dermatite atópica

Comentar este artigo

Você precisa estar logado para comentar os artigos.
Desenvolvido por logo-crowd